Ennar Pharmaceuticals

Ennar Pharma AG ("Ennar Pharmaceuticals") was a Swiss private pharmaceutical company established in 2010 that focused on developing small-molecule therapies for dermatological diseases such as eczema and skin ulcers. Its two main assets—ENN‑10 for eczema and ENN‑11 for skin ulcers—were both discontinued by early 2025. The firm has no current clinical-stage assets or ongoing R&D activities. There are no signs it has been acquired or remains operational as an innovator pharma business.[1] Other similarly named entities like "Ennar Exports" operate solely as distributors/exporters from India without any drug discovery/development activity.[3][5][9]